Risk of Chronic Kidney Disease Progression

Completed

Conditions studied: Chronic Kidney Disease, End Stage Renal Disease

In brief

While there are proven therapies that slow CKD progression, these therapies can at times be harmful and costly. The ability to accurately predict the risk of CKD progression to ESRD would be extremely valuable. The short term versus lifetime risk of CKD progression should be taken into account when making risk based clinical decisions. In a representative CKD practice, the investigators compared the short term and lifetime risk assessment in our stage 3 CKD patients to determine whether decisions based on a short term risk assessment would underestimate the lifetime risk of CKD progression. The investigators also applied the short term risk assessment to our stage 4 CKD patients to determine the frequency with which ESRD risk may be overestimated in CKD stage 4.

Key facts

Study ID

NCT02654756

Run by

Winthrop University Hospital

People needed

623

Starts

2013-05-01

Expected to finish

2018-11-01

Last updated by the study team

2023-02-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Evaluation at least once by a nephrologist in the past year.
• Subjects must have recent pertinent laboratory data within the last 2 years.
• 2 documented creatinine values separated by at least 3 months

You may not qualify if…

• Deceased patients
• estimated GFR < 15ml/min
• Patients with Acute Renal Failure (ARF)

Where it is running

• NYU Winthrop — Mineola, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.